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Background: Insulin like growth factor binding proteins modulate the mitogenic and pro survival effects of IGF.
Elevated expression of IGFBP2 is associated with progression of tumors that include prostate, ovarian, glioma
among others. Though implicated in the progression of breast cancer, the molecular mechanisms involved in
IGFBP2 actions are not well defined. This study investigates the molecular targets and biological pathways targeted
by IGFBP2 in breast cancer.
Methods: Transcriptome analysis of breast tumor cells (BT474) with stable knockdown of IGFBP2 and breast tumors
having differential expression of IGFBP2 by immunohistochemistry was performed using microarray. Differential
gene expression was established using R-Bioconductor package. For validation, gene expression was determined by
qPCR. Inhibitors of IGF1R and integrin pathway were utilized to study the mechanism of regulation of β-catenin.
Immunohistochemical and immunocytochemical staining was performed on breast tumors and experimental cells,
respectively for β-catenin and IGFBP2 expression.
Results: Knockdown of IGFBP2 resulted in differential expression of 2067 up regulated and 2002 down regulated
genes in breast cancer cells. Down regulated genes principally belong to cell cycle, DNA replication, repair, p53
signaling, oxidative phosphorylation, Wnt signaling. Whole genome expression analysis of breast tumors with or
without IGFBP2 expression indicated changes in genes belonging to Focal adhesion, Map kinase and Wnt signaling
pathways. Interestingly, IGFBP2 knockdown clones showed reduced expression of β- catenin compared to control
cells which was restored upon IGFBP2 re-expression. The regulation of β-catenin by IGFBP2 was found to be IGF1R
and integrin pathway dependent. Furthermore, IGFBP2 and β-catenin are co-ordinately overexpressed in breast
tumors and correlate with lymph node metastasis.
Conclusion: This study highlights regulation of β-catenin by IGFBP2 in breast cancer cells and most importantly,
combined expression of IGFBP2 and β-catenin is associated with lymph node metastasis of breast tumors.
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The Insulin like Growth Factor binding proteins (IGFBP)
are a family of six proteins that bind with high affinity to
Insulin like growth factors (IGF-I and IGF-II), prolong their
half-life in circulation and thereby regulate IGF actions.
Insulin like growth factor binding protein 2 (IGFBP2) is the
second most abundant IGFBP in circulation and in a
context dependent manner it can either inhibit or
potentiate the actions of IGF [1], thereby modulating the
prosurvival and/or mitogenic effects of IGF. Elevated
expression of IGFBP2 has been observed in multiple
malignancies, including Glioblastoma multiforme [2-4],
ovarian [5,6], pancreatic [7], gastric [8], prostate [9],
colon [10], breast [11,12], leukemia [13] and thyroid
cancer [14]. In addition, increased expression of IGFBP2
has been correlated with poor prognosis in prostate, glio-
blastoma and colon cancers [15-18]. It has been reported
that IGFBP2 inhibits the IGF dependent proliferation of
normal cells while in tumor cells, it promotes proliferation
in an IGF1R dependent or independent manner [19,20].
Pro proliferative action of IGFBP2 has been reported in
prostate, ovarian and colon cancer cells and non-
transformed rat osteoblasts [19,21-24]. IGFBP2 expression
has also been shown to enhance migration and invasion in
glioma, ovarian and bladder cancer cells [3,25-27]. Recent
studies in glioma implicate IGFBP2 in the activation of
PI3K Akt pathway [28], integrin/ILK/NF-B network which
drives glioma progression in mice [29] and binding to
integrin α5 [30] that brings about increased migration and
invasion. In breast cancer, IGFBP2 over expression has
been shown to confer drug resistance [11] and increased
expression has been reported to correlate with lymph
node metastasis In T1 breast carcinomas [31]. However,
mechanisms that govern IGFBP2 actions in breast cancers
are poorly understood.
In the present study, to elucidate the cellular pathways
influenced by IGFBP2 in breast cancer, gene expression
profiling of IGFBP2 knockdown breast cancer cells was
compared with the expression profile of IGFBP2 positive
breast tumors. Our results highlight regulation of cell
cycle and Wnt signaling pathways by IGFBP2. Most
significantly, our data shows for the first time that the
concomitant over expression of IGFBP2 and β-catenin
in breast cancer is associated with increased incidence of
lymph node metastasis.
Results
IGFBP2 perturbation by shRNA alters gene expression
profile in breast cancer cells
In view of the pro-tumorigenic actions of IGFBP2
reported in several cancers including breast tumors, we
decided to delineate the molecular mechanism of
IGFBP2 actions in breast cancers. Initially, stable sub
lines of breast tumor cell line BT474 with knockdown ofIGFBP2 were generated. Among several clones, two of
the clones (C5 and C12) that showed considerable knock
down of IGFBP2 (Figure 1a) were selected for further
studies. Transcriptome analysis of the IGFBP2 knock
down cells using Agilent whole human genome 4x44K
arrays was performed against control cells (vector
transfected). Data analysis revealed significant regulation
of 4069 probes in both the clones compared to control
cells. Among these, 2067 probes showed up regulation
while 2002 probes showed down regulation (Additional
file 1: Table S1). Hierarchical cluster revealed similar
expression pattern of regulated genes in both the clones
(Figure 1b). The list of top 25 up and down regulated
genes is shown in Table 1. The differentially regulated
genes were subjected to pathway enrichment analysis
using GSEA (Table 2). This analysis revealed enrichment
of down regulated genes belonging to cell cycle, DNA
replication, repair, p53 signaling, oxidative phosphorylation,
Wnt signaling, etc. qPCR analysis of some genes validated
differential expression seen in microarray data (Figure 1c).
Over expression of IGFBP2 in the knockdown cells
resulted in up regulation of IGF1R, IGF2, TOP2A, p53,
CCND1 and FOXM1 genes which were down regulated
upon IGFBP2 knockdown (Additional file 2: Figure S1)
suggesting the specificity of the regulation of these genes
by IGFBP2. Hence, perturbation of IGFBP2 results in
differential expression of several genes and pathways.
Differential expression of genes between tumors staining
positive or negative for IGFBP2
In order to determine, whether expression of IGFBP2
regulated genes as revealed by IGFBP2 perturbation is
also altered in tumors, we studied the gene expression
patterns in tumors based on IGFBP2 expression. We
selected 12 IGFBP2 positive and 7 IGFBP2 negative
tumor RNAs for microarray expression analysis using
Agilent whole human genome 4x44K arrays. Comparison
of gene expression profiles between IGFBP2 positive and
negative tumors revealed 3460 probes as significantly
differentially regulated. Among them, 1635 probes were
up regulated and 1825 probes were found to be down
regulated in IGFBP2 positive tumors compared to IGFBP2
negative tumors (Additional file 3: Table S2). List of top
25 up or down regulated genes are shown in Table 3. To
identify enriched pathways associated with differentially
expressed genes, Gene set enrichment analysis (GSEA)
was carried out. The genes up regulated in IGFBP2
positive tumor samples showed significant enrichment
in Focal adhesion, MAPK signaling pathway, apoptosis,
Chemokine signaling, cytokine-cytokine receptor inter-
action and ECM receptor interaction and Wnt signaling
pathway (Table 4). Hierarchical cluster (Euclidean distance
method) of log2 transformed differentially expressed genes
between IGFBP2 positive and negative tumors revealed
a 
b c
Figure 1 IGFBP2 regulated genes in BT474 breast cancer cells. a) Western blot analysis of IGFBP2 in the supernatant of IGFBP2 knockdown
clones C5 and C12 and control cells. Lower panel is ponceau stained membrane shown as loading control. b) Hierarchical cluster of differentially
expressed genes in IGFBP2 knockdown BT474 cells versus control cells. Differentially regulated genes were clustered using MeV software. The
dendrogram on the left shows different clusters of genes segregated according to the pattern of regulation. Red and green indicate high and
low expression of genes respectively. Black indicates no regulation. c) Validation of selected genes by qPCR. Bar graphs of differentially regulated
genes in IGFBP2 Knockdown BT474 clones versus control cells. The graphs represent the fold change over control after normalization with the
expression of RPL35a.
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IGFBP2 positive or negative tumors. However, in one
cluster, there is a sub cluster representing exclusively
IGFBP2 positive tumors (Figure 2a). Microarray results
were validated on few genes by qPCR. As shown in
Figure 2b, qPCR revealed that CCND1(Cyclin D1),
CDC42, GATA 3, SYT13 and SFRP2 and TMEM49 as up
regulated in IGFBP2 positive tumors while IGFBP2,
NR4A2 and SFRP2 were down regulated in IGFBP2
negative tumors. In addition, since Wnt pathway genes
were significantly regulated in IGFBP2 knock down cells,
we studied the expression of Wnt target genes in IGFBP2
positive and negative breast tumors. The Wnt target genes
CCND1, SFRP2 (Figure 2b) MCAM, SP5 and IGF1
(Additional file 4: Figure S2) were found to be differentially
expressed between IGFBP2 positive and negative tumors.
Taken together, the data from the IGFBP2 knockdown
cells and IGFBP2 positive breast tumors suggest a positivecorrelation of IGFBP2 with pro-tumorigenic pathways
including Wnt pathway in breast cancer.
Common genes differentially expressed in breast tumors
and cell lines based on IGFBP2 expression
In the previous experiments, we identified genes differen-
tially expressed in breast tumors and breast cancer cells
lines based on IGFBP2 expression. In order to identify the
genes commonly regulated by IGFBP2 in cell lines and
tumors, we compared the gene expression profiles of
IGFBP2 positive versus negative tumors and IGFBP2
knockdown breast cancer cells. 654 probes were found to
be common among IGFBP2 regulated genes in tumors and
cell line. Among these 412 probes were down regulated in
IGFBP2 positive tumors and up regulated upon IGFBP2
knockdown while 242 probes were up regulated in IGFBP2
positive tumors and down regulated upon IGFBP2 knock-
down (Additional file 5: Table S3). Some genes that are
Table 1 List of top 50 differentially regulated genes
(p < 0.05) in IGFBP2 knockdown clones
Probe Gene symbol Accession no. LOG2 ratios IGFBP2
(shRNA/scrambled)
C5 C12
A_23_P70007 HMMR NM_012484 −6.1994 −6.3340
A_23_P115872 CEP55 NM_018131 −5.5493 −5.7555
A_23_P155815 HCAP-G NM_022346 −5.9516 −5.6434
A_23_P49878 FAM64A NM_019013 −5.3231 −5.5775
A_23_P401 CENPF NM_016343 −5.6859 −5.5456
A_24_P297539 UBE2C NM_181803 −6.0374 −5.5064
A_23_P52017 ASPM NM_018136 −5.6626 −5.4146
A_23_P118815 BIRC5 NM_001012271 −5.7127 −5.3579
A_23_P51085 SPBC25 NM_020675 −5.3333 −5.2314
A_32_P62997 PBK NM_018492 −5.3592 −5.1651
A_23_P379614 OIP5 NM_007280 −5.4136 −5.0805
A_23_P138507 CDC2 NM_001786 −5.3918 −4.9418
A_23_P74349 CDCA1 NM_145697 −5.0628 −4.7854
A_23_P375 CDCA8 NM_018101 −4.9988 −4.7055
A_23_P385861 CDCA2 NM_152562 −4.8413 −4.6523
A_23_P107421 TK1 NM_003258 −5.1628 −4.6138
A_23_P50108 KNTC2 NM_006101 −4.5643 −4.6060
A_23_P124417 BUB1 NM_004336 −4.8189 −4.5874
A_23_P88331 DLG7 NM_014750 −4.8666 −4.5641
A_23_P118834 TOP2A NM_001067 −4.9585 −4.5030
A_24_P234196 RRM2 NM_001034 −4.6703 −4.4466
A_23_P65757 CCNB2 NM_004701 −4.6828 −4.4265
A_23_P119943 IGFBP2 NM_000597 −2.4765 −4.4074
A_23_P88731 RAD51 NM_002875 −4.9625 −4.3833
A_23_P133123 MND1 NM_032117 −4.6389 −4.3051
A_23_P31407 AGR2 NM_006408 4.8060 4.2255
A_23_P106194 FOS NM_005252 2.1989 4.2063
A_23_P429998 FOSB NM_006732 1.5980 3.8822
A_23_P113952 AY227436 AY227436 3.4910 3.8165
A_23_P500000 SCEL NM_144777 3.6586 3.2728
A_23_P169437 LCN2 NM_005564 2.5385 3.2159
A_23_P380754 PRSS1 NM_002769 2.3278 3.1664
A_23_P29773 LAMP3 NM_014398 4.2963 3.1041
A_23_P5983 PLTP NM_006227 1.3270 2.8955
A_23_P310274 PRSS2 NM_002770 2.0382 2.8886
A_23_P71170 TRPV6 NM_018646 2.6719 2.7426
A_23_P98121 FXYD4 NM_173160 3.0264 2.6979
A_23_P88095 TBC1D4 NM_014832 0.9759 2.6576
A_32_P230828 GAS5 NR_002578 1.9990 2.6280
A_23_P369343 KLK8 NM_144505 2.0683 2.5972
A_23_P18684 CLGN NM_004362 2.4448 2.5689
A_32_P37592 SCARNA17 NR_003003 1.7724 2.5574
Table 1 List of top 50 differentially regulated genes
(p < 0.05) in IGFBP2 knockdown clones (Continued)
A_23_P22735 BEX2 NM_032621 3.3099 2.5138
A_24_P921446 EMP1 BC017854 1.1796 2.4896
A_23_P121926 SEPP1 NM_005410 2.7851 2.4722
A_23_P34915 ATF3 NM_004024 3.5213 2.4288
A_23_P105803 FGF9 NM_002010 0.9259 2.3751
A_24_P327886 TCEA3 NM_003196 2.1369 2.3522
A_23_P391344 RASGEF1A NM_145313 3.5570 2.3442
A_24_P18190 HSPA5 NM_005347 2.8335 2.3293
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Genes such as FBLN1, ID1, FN1, LMO2, DCK, TLR4
which have important roles in tumor progression were up
regulated in IGFBP2 positive tumors and were decreased
upon IGFBP2 knockdown in breast cancer cells whereas
genes such as SRPRB, POPDC3, ARHGEF4, KCNN4,
BC11A which have negative role in tumorigenesis were
down regulated in IGFBP2 positive tumors and were up
regulated in IGFBP2 negative cells (p < 0.05). These results
indicate that these genes or the pathways associated with
these genes could be truly regulated by IGFBP2 in breast
cancer. Some of these genes/pathways may have a role in
IGFBP2 mediated tumor progression.
KEGG pathway analysis of common differentially
regulated genes between IGFBP2 perturbed cells and
IGFBP2 positive tumors revealed that the regulated
genes belong to Glioma, Oxidative Phosphorylation,
Apoptosis, Pathways in cancer and ErbB signaling
pathway (Additional file 6: Table S4).Taken together, these
data indicate that tumors with IGFBP2 expression
phenotype are associated with distinct changes in
expression of genes associated with the regulation of cell
proliferation and tumorigenicity.β-catenin expression is regulated by IGFBP2 in breast
cancer cells
Since the GSEA analysis of differentially expressed genes
in both tumors and knockdown cells revealed significant
regulation of Wnt signaling pathway, we decided to
examine if IGFBP2 regulates Wnt pathway. As β-catenin
is an effector of Wnt pathway we determined β-catenin
expression in IGFBP2 knockdown cells. As shown in
Figure 3, knockdown of IGFBP2 in BT474 breast cancer
cells substantially decreased the expression of β-catenin in
both the clones C5 and C12, suggesting a direct regulation
of β-catenin by IGFBP2. In good correlation, when
IGFBP2 expression is restored in the knockdown cells,
β-catenin expression is also restored (Figure 4). These
results collectively demonstrate regulation of β-catenin
expression by IGFBP2.
Table 2 GSEA summary of pathways associated with genes down regulated upon IGFBP2 knockdown
NAME SIZE NOM p-val FDR q-val FWER p-val
KEGG_CELL_CYCLE 49 0 0 0
KEGG_DNA_REPLICATION 28 0 0 0
KEGG_NUCLEOTIDE_EXCISION_REPAIR 15 0 0 0
KEGG_MISMATCH_REPAIR 15 0 0 0
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 15 0 2.19E-04 0.001
KEGG_HOMOLOGOUS_RECOMBINATION 15 0 1.83E-04 0.001
KEGG_PYRIMIDINE_METABOLISM 21 0 1.56E-04 0.001
KEGG_OXIDATIVE_PHOSPHORYLATION 19 0 0.00635 0.039
KEGG_PARKINSONS_DISEASE 21 0 0.01229 0.082
KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION 17 0.006186 0.013514 0.098
KEGG_SPLICEOSOME 32 0.002012 0.01617 0.128
KEGG_OOCYTE_MEIOSIS 30 0 0.02404 0.199
KEGG_P53_SIGNALING_PATHWAY 26 0 0.027815 0.247
KEGG_HUNTINGTONS_DISEASE 30 0.004098 0.032137 0.3
KEGG_WNT_SIGNALING_PATHWAY 21 0.045726 0.138961 0.804
KEGG_PURINE_METABOLISM 26 0.047431 0.150692 0.844
KEGG_GAP_JUNCTION 17 0.15251 0.155502 0.877
KEGG_TGF_BETA_SIGNALING_PATHWAY 15 0.393214 0.318836 0.995
KEGG_SMALL_CELL_LUNG_CANCER 15 0.55144 0.400925 0.999
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 25 0.517578 0.687552 1
KEGG_TIGHT_JUNCTION 16 0.787018 0.687305 1
KEGG_PATHWAYS_IN_CANCER 52 0.229814 0.731651 1
KEGG_ALZHEIMERS_DISEASE 38 0.433663 0.706543 1
NOM P nominal P value.
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are mediated in part by the activation of IGF1 receptor
and also through integrin receptors [20]. Hence, in order
to identify the intermediates of IGFBP2 regulation of
β-catenin, we studied the effect of IGF1R inhibitor
(PPP, 10 μM) and Focal Adhesion Kinase inhibitor
(PP2, 10 μM) on the regulation of β-catenin by IGFBP2.
As described above, over expression of IGFBP2 in the
knockdown clones increased β-catenin expression and in
the presence of IGF1R inhibitor or FAK inhibitor, IGFBP2
induced β-catenin expression was abolished (Figure 4).
Similar results were obtained using MDA-MB-231 cells
which lack endogenous IGFBP2 expression (Additional
file 7: Figure S3). These results suggest that IGFBP2
regulates β-catenin expression in an IGF1R and integrin
dependent manner.IGFBP2 and β-catenin staining together correlates with
the lymph node metastasis in human breast cancer
Since the previous results showed an increase in β-catenin
expression upon IGFBP2 over expression, we sought to
examine the correlation of β-catenin and IGFBP2 stainingin human breast cancer tissues. Towards this we
performed IHC on 38 grade III Invasive Ductal Carcinoma
tissues for β-catenin and IGFBP2 expression. A represen-
tative staining pattern of IGFBP2 and β-catenin expression
is depicted in Figure 5. It was observed that 27 out of 38
tumors stained positive for IGFBP2. There was a positive
correlation between IGFBP2 and β-catenin expression
with 26 out of 27 IGFBP2 positive tumor samples also
staining positive for β-catenin (Table 6). Tissues with
β-catenin expression exhibited a heterogeneous mixture
of membranous and cytosolic β-catenin accumulation. In
addition, more lymph node metastasis was observed in
patients positive for both IGFBP2 and β-catenin proteins
(18/24, 75%) compared with patients with low levels of
both proteins (1/24, 4%) (p = 0.0006).
No significant association of combined expression of
IGFBP2 and β-catenin was observed with ER, PR, Her2
or triple negative receptor status of breast tumors.Discussion
Enhanced expression of IGFBP2 is associated with a
large number of malignant cancers that include tumors
Table 3 List of top 50 differentially regulated genes
(p < 0.05) in IGFBP2 positive versus IGFBP2 negative tumors
Probe Gene name Accession no. Fold change
IGFBP2 +/ IGFBP2-
A_23_P161940 SCGB2A2 NM_002411 4.2566
A_23_P8702 PIP NM_002652 2.8894
A_24_P137501 SFRP2 NM_003013 2.4919
A_23_P312300 SCGB2A1 NM_002407 2.4797
A_24_P347431 FOXA1 NM_004496 2.4462
A_23_P372234 CA12 NM_001218 2.3044
A_23_P393099 TFF3 NM_003226 2.2590
A_23_P215328 SFRP4 NM_003014 2.2567
A_23_P213745 CXCL14 NM_004887 2.1824
A_23_P413641 PREX1 NM_020820 2.1719
A_23_P99063 LUM NM_002345 2.1563
A_23_P75056 GATA3 NM_001002295 2.0939
A_24_P322771 TFF1 NM_003225 2.0888
A_23_P119943 IGFBP2 NM_000597 2.0290
A_23_P161659 SYT13 NM_020826 1.9984
A_23_P329768 GREB1 NM_014668 1.9528
A_23_P105212 THRSP NM_003251 1.9163
A_23_P95594 NAT1 NM_000662 1.9107
A_24_P264943 COMP NM_000095 1.8625
A_23_P89431 CCL2 NM_002982 1.8472
A_32_P133072 SPON1 NM_006108 1.8374
A_23_P33196 COL5A2 NM_000393 1.8357
A_23_P2920 SERPINA3 NM_001085 1.8217
A_23_P22970 PIK3R3 NM_003629 1.7963
A_23_P165778 MLPH NM_024101 1.7915
A_32_P184464 ROPN1 NM_017578 −3.5588
A_23_P328545 GABRP NM_014211 −2.9846
A_23_P66137 SOX8 NM_014587 −2.7293
A_24_P417407 ROPN1B NM_001012337 −2.5309
A_23_P53176 FOLR1 NM_016725 −2.3657
A_23_P56197 CRLF1 NM_004750 −2.2530
A_23_P369343 KLK8 NM_144505 −2.2248
A_24_P236251 DLK1 NM_003836 −2.1531
A_23_P78248 KRT23 NM_015515 −2.1320
A_23_P47484 GLYATL2 NM_145016 −2.1208
A_23_P10127 SFRP1 NM_003012 −2.0505
A_23_P40108 COL9A3 NM_001853 −2.0500
A_23_P47616 FOLH1 NM_004476 −1.8461
A_23_P50815 TTYH1 NM_020659 −1.7817
A_23_P137173 TMSL8 NM_021992 −1.7054
A_23_P110234 CSN1S1 NM_001890 −1.6859
A_23_P216448 NFIB NM_005596 −1.6243
A_23_P78980 B3GNT3 NM_014256 −1.5946
Table 3 List of top 50 differentially regulated genes
(p < 0.05) in IGFBP2 positive versus IGFBP2 negative tumors
(Continued)
A_24_P924484 K03200 K03200 −1.5836
A_32_P157391 PSMAL NM_153696 −1.4833
A_23_P110837 IRX4 NM_016358 −1.4820
A_23_P43157 MYBL1 X66087 −1.4800
A_23_P59960 CRISPLD1 NM_031461 −1.4630
A_23_P422212 SLC35F3 NM_173508 −1.4618
A_23_P37205 NDRG2 NM_201535 −1.4531
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for its growth inhibitory actions in physiological context,
IGFBP2 has now been shown to promote growth and
tumorigenesis in numerous cancer cells such as glioma,
prostate and colon cancers [15-18]. To gain further
insights into the role of IGFBP2 in breast cancer, we
have attempted to identify the molecular players in
IGFBP2 associated tumorigenesis in breast cancer. To
elucidate the molecular targets of IGFBP2, we perturbed
IGFBP2 expression by shRNA and the differential
gene expression was determined using whole genome
microarrays. IGFBP2 knockdown resulted in significant
changes in the expression of genes associated with cellular
proliferation and tumorigenicity. The down regulated
genes were found to be associated with several pathways,
notably Cell cycle, p53 and Wnt pathways as revealed
by GSEA. Comparison of our data with a previous
microarray study of IGFBP2 regulated genes in glioma
cells [29] revealed an overlap of about 22% genes with
wild type IGFBP2 over expressing cells and 23% genes
with RGE mutant IGFBP2 over expressing cells. Pathway
comparisons revealed Cell cycle, p53 signaling, oxidative
phosphorylation, nucleotide metabolism and Wnt signaling
pathway to be common among the two data sets
(Additional file 8: Figure S4). To further validate these
results in breast cancer tissues, we performed whole
genome expression analysis in 19 breast tumors which
were categorized as IGFBP2 positive or negative based
on immunohistochemical staining pattern. Compared
to IGFBP2 negative tumors, IGFBP2 positive tumors
showed increased expression of genes belonging to MAPK
signaling, Focal adhesion and Wnt signaling.
IGFBP2 correlation with proliferation has been studied
extensively in several tumor cells including in breast
cancer cells. The effect of IGFBP2 on proliferation has
been shown to be context dependent. In prostate, ovarian,
nephroblastoma cells, it has a pro proliferative action
[19,21-24]. In contrast IGFBP2 has an antiproliferative
effect on HEK, Hs578T [32,33]. Our data on the regulation
of different pathways such as MAPK, Cell cycle, Focal
adhesion and Wnt corroborate the reported functional
Table 4 GSEA summary of pathways associated with genes up regulated in IGFBP2 positive tumors
NAME SIZE NOM p-val FDR q-val FWER p-val
KEGG_MAPK_SIGNALING_PATHWAY 43 0 0 0
KEGG_LEISHMANIA_INFECTION 20 0 0 0
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 35 0 0.007717 0.013
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 19 0.001976 0.006687 0.015
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 19 0.00211 0.016915 0.045
KEGG_FOCAL_ADHESION 30 0.007619 0.025984 0.084
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 16 0.015968 0.023016 0.087
KEGG_ECM_RECEPTOR_INTERACTION 15 0.002053 0.022288 0.096
KEGG_CHEMOKINE_SIGNALING_PATHWAY 32 0.008403 0.020502 0.1
KEGG_APOPTOSIS 20 0.008584 0.018452 0.1
KEGG_VIRAL_MYOCARDITIS 17 0.005906 0.017723 0.105
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 27 0.028902 0.037213 0.228
KEGG_GNRH_SIGNALING_PATHWAY 19 0.044444 0.113272 0.563
KEGG_CELL_ADHESION_MOLECULES_CAMS 26 0.095808 0.195608 0.805
KEGG_ALZHEIMERS_DISEASE 24 0.087302 0.183226 0.805
KEGG_PATHWAYS_IN_CANCER 48 0.098 0.185527 0.831
KEGG_AXON_GUIDANCE 17 0.11553 0.176978 0.834
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 24 0.136538 0.210733 0.893
KEGG_DILATED_CARDIOMYOPATHY 15 0.165339 0.237117 0.925
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 19 0.168932 0.240447 0.932
KEGG_MELANOGENESIS 15 0.252033 0.367091 0.99
KEGG_LYSOSOME 18 0.329389 0.436596 0.996
KEGG_CALCIUM_SIGNALING_PATHWAY 19 0.367886 0.427407 0.996
KEGG_WNT_SIGNALING_PATHWAY 24 0.361616 0.414545 0.996
KEGG_ENDOCYTOSIS 20 0.365503 0.423908 0.998
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 15 0.419958 0.454951 0.999
KEGG_HUNTINGTONS_DISEASE 18 0.568465 0.60777 1
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 29 0.74269 0.769736 1
KEGG_PURINE_METABOLISM 20 0.933054 0.931545 1
NOM P nominal P value.
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http://www.molecular-cancer.com/content/12/1/63significance of IGFBP2 with respect to its pro proliferative
and tumor promoting roles in breast cancer cells.
One of the important and novel findings from this
study is the regulation of Wnt signaling pathway genes
by IGFBP2. So far, only IGFBP4 has been reported to
activate Wnt signaling pathway in renal cell carcinoma
[34]. Activation of canonical Wnt signaling promotes
tumorigenesis by regulating cell survival, proliferation
and invasion of many cancers [35]. In numerous tumors
cytoplasmic and/or nuclear accumulation of β-catenin
has been shown to be a strong indicator of aberrant
Wnt pathway activation. Elevated cytosolic and nuclear
accumulation of β-catenin has been associated with a
variety of malignancies and inversely correlated with
patient survival [36-39], Wnt activation leads to stabilizationand translocation of β-catenin from cytoplasm to the
nucleus where it associates with T-cell factor (TCF)/
lymphocyte enhancer transcription (LEF) factors to acti-
vate target genes that are involved in cell survival, pro-
liferation, and invasion [40,41]. In order to establish
Wnt pathway activation by IGFBP2, we examined the
canonical Wnt signaling target, β-catenin in IGFBP2
knockdown breast cancer cells. Compared to Vector
transfected cells, IGFBP2 knockdown cells showed
remarkably decreased levels of β-catenin. When IGFBP2
was re expressed in the knockdown cells, as expected there
was substantial increase in β-catenin levels indicating
that IGFBP2 regulates β-catenin. Interestingly, inhibition
of IGF1R or integrin signaling resulted in the loss of











Figure 2 Differential expression of genes in IGFBP2 positive and IGFBP2 negative tumor samples compared to control tissues. a) Genes
were clustered using MeV software. The dendrogram on the left shows different clusters of genes segregated according to the pattern of
regulation. Red and green indicate high and low expression of genes respectively. Black indicates no regulation. b) Validation of selected genes.
Scatter plots of differentially regulated genes in IGFBP2 positive and IGFBP2 negative tumors compared to the expression in normal tissues. Log
2-transformed gene expression ratios obtained from real-time quantitative PCR analysis normalized to TBP expression are plotted. Each dot
represents a data derived from one sample.
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http://www.molecular-cancer.com/content/12/1/63that IGFBP2 acts through IGF1R and integrin pathways in
the regulation of β-catenin. Although the mechanisms are
not clear, recently Uzoh et al. demonstrated an increased
proliferation of prostate cancer cells by IGFBP2 in an
IGF1R dependent manner [20]. It is also known that IGF
independent actions of IGFBP2 are mediated by the
activation of integrin signaling through RGD motif present
in the C-terminal region of IGFBP2 protein [30]. Role of
integrin receptors in pro-tumorigenic action of tumor
cells is well established [42,43]. Hence, it is conceivable
that activation of integrin signaling by IGFBP2 leading toFAK phosphorylation may be an important step in the
activation of IGF1R by IGFBP2. In congruence with this,
it has been reported that activated FAK phosphorylates
and stabilizes IGF1R in mouse embryonic fibroblast [44].
Very recently, IGFBP2 in association with IGF1 was found
to activate IGF1R in endothelial cells [45]. Taken together,
regulation of Wnt pathway by IGFBP2 involves FAK and
IGF1R in breast carcinogenesis. However, the mechanism
(s) by which FAK and IGF1R signaling converge on the
regulation of Wnt pathway by IGFBP2 needs further
investigations.
Table 5 List of top 50 common genes differentially
regulated between IGFBP2 positive tumors and IGFBP2
knockdown clones
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http://www.molecular-cancer.com/content/12/1/63Another important finding from our data is the
correlation of IGFBP2 over expression with elevated
β-catenin levels in breast tumors. In humans, breast
tumors frequently exhibit elevated levels of IGFBP2 [12]
and β-catenin, with higher expression levels of β-catenin
correlating with a decreased patient survival [39]. In mice,
over expression of an activated β-catenin leads to the
development of mammary hyperplasia and adenocarcinomas
[46]. These studies coupled with our data suggest that
regulation of β-catenin could be an important step for the
pro-tumorigenic actions of IGFBP2. Most significantly,
when both IGFBP2 and β-catenin expression was corre-
lated with the lymph node status of breast cancers, we
found a significant association of IGFBP2 and β-catenin
staining with increased lymph node metastasis in com-
parison with tumors which did not show staining for
either protein. Interestingly, in a previous report, expression
of IGFBP2 and IGFBP5 were correlated with increasedFigure 3 β-catenin and IGFBP2 expression in IGFBP2
knockdown and control cells. IGFBP2 knockdown clones and
control cells were plated on coverslips and allowed to grow.
24 h after plating, cells were fixed, permeabilized, and stained for
β-catenin and IGFBP2 expression. Expression of β-catenin and
IGFBP2 is shown in green and blue, respectively. Nucleus was
stained using propidium iodide (PI) as shown in red. Original
magnification was 63×.
Figure 4 Regulation of β-catenin by IGFBP2 is IGF1R and FAK
dependent. IGFBP2 knockdown clone C12 was transfected with
IGFBP2 and 36 h. after transfection cells were fixed and analyzed for
β-catenin, and IGFBP2. For inhibitor experiments, 24 h. after
transfection cells were treated with IGF1R or FAK inhibitor for 12 h.
Cells were fixed and analyzed for β-catenin and IGFBP2 expression.
Expression of β-catenin and IGFBP2 is shown in green and blue,
respectively. Nucleus was stained using propidium iodide (PI) as
shown in red. Original magnification was 63×. V, Vector control; OE,
Over expression; Inh, inhibitor.
Table 6 IGFBP2 and β-catenin expression in breast cancer
tissues
S. No. Case No. IGFBP2 β-catenin Nodal status
1 160 + + +
2 159 + + -
3 157 + + -
4 171 + + +
5 150 + - +
6 151 - + +
7 180 + + -
8 176 + + +
9 174 + + +
10 168 + + +
11 165 + + +
12 162 + + -
13 149 + + +
14 148 + + +
15 143 + + +
16 142 + + +
17 140 + + +
18 138 + + -
19 137 + + -
20 134 + + +
21 133 + + -
22 132 + + -
23 130 + + +
24 70 + + +
25 94 - - -
26 87 + + +
27 49 + + +
28 63 + + +
29 117 + + +
30 108 - + +
31 96 - - -
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http://www.molecular-cancer.com/content/12/1/63lymph node metastasis in T1 breast carcinoma. However
our data shows a significant positive correlation of
IGFBP2 and β-catenin in lymph node metastasis. Hence,
evaluation of IGFBP2, IGFBP5 along with β-catenin may
provide a stronger predictive value for the prognosis of
breast cancer.Figure 5 β-catenin and IGFBP2 expression in breast cancer
tissues. Representative micrographs showing β-catenin staining in
cancer tissues. a β-catenin staining of a section of IDC 3 breast
tumors showing cytoplasmic and membrane staining. b represents
breast cancer tissue section stained for IGFBP2 showing
predominantly cytoplasmic staining.
32 85 - + -
33 77 - - +
34 48 - + +
35 57 - + +
36 78 - + +
37 30 - - -
38 31 - - -Conclusion
This study highlights the pathways and genes regulated
by IGFBP2 in breast cancer. Most importantly, this study
reports regulation of β-catenin by IGFBP2 and their
association in the lymph node metastasis. These findings
Sehgal et al. Molecular Cancer 2013, 12:63 Page 11 of 14
http://www.molecular-cancer.com/content/12/1/63are highly relevant in the prediction of breast cancer
progression.
Methods
All the tissues for this study were collected after
obtaining written informed consent from the patients.
This study and the protocols were approved by the
Institutional Ethics Committee of Kidwai Memorial
Institute of Oncology, where the patients were treated.
Cell culture and transfection
BT474, a breast cancer cell-line was cultured in DMEM
(Sigma-Aldrich, USA) with 10% foetal bovine serum (FBS),
100 units/ml penicillin and 100 μg/ml streptomycin,
2.5 μg/ml fungizone (Invitrogen Life Sciences, USA).
All the cells were maintained at 37°C in a humid
atmosphere with 5% CO2. Transfections were performed
using Lipofectamine 2000 (Invitrogen) based on the
manufacturer’s instructions. In brief, breast cancer cells
were transfected with IGFBP2 shRNA expression vector
(Origene, Cat no. TR316590) or empty vector (Origene,
Cat no. TR20003) and 48 hrs after transfection puromycin
(1 μg/ml, Calbiochem) was added to the growth medium.
Selection medium was replaced every 2–3 days until
individual clones could be identified. After 3 weeks of
selection, fourteen puromycin resistant clones of BT474
cells were isolated and expanded in the selective medium.
Two clones (C5 and C12) which showed significant down
regulation of IGFBP2 expression were selected for further
experiments Reversion of IGFBP2 expression in IGFBP2
knockdown cells was achieved by transfecting IGFBP2
cDNA sub cloned into pcDNA3.1 vector (Invitrogen).
Pathway inhibitor treatments were performed using IGF1R
inhibitor (PPP, 10 μM, Calbiochem Cat. No. 407247) and
Focal Adhesion Kinase inhibitor (PP2, 10 μM, Calbiochem
Cat. No. 529573).
Immunoblot analysis
For immunoblot analysis, cells were grown in growth
medium till they achieved 50-70% confluency, washed
with serum free DMEM and cultured in serum free
medium for another 48 h. The spent medium was
collected, concentrated using centrifugal filter units
(Millipore, Amicon ultra-3 k) and equal amounts of
protein as determined by the Bio-Rad DC protein assay
(Bio-Rad, USA) were separated on 12.5-15% polyacryl-
amide gel and electrophoretically transferred onto PVDF
membranes (Immobilin P, Millipore). Membranes were
pre-incubated for 1 h with 5% non-fat dry milk (Fluka,
Sigma-Aldrich) in Tris buffered-saline containing 0.1%
Tween 20 (TBST) and then were incubated overnight
with primary antibody. (IGFBP2 C-18: sc-6001, Santa
Cruz Biotechnology, Inc, CA). Membranes were washed
thrice for 15 min in TBST at room temperature,incubated with appropriate horseradish-peroxidase con-
jugated IgG (Sigma-Aldrich) at a dilution of 1:2000 for
1 h at room temperature and the complex detected
using Super Signal West Femto chemiluminescence
(Pierce, Thermo Scientific), as per the manufacturer’s
instructions.
RNA extraction and gene expression profiling
Total RNA from frozen tumor tissues and tumor cells
was extracted using the TRI reagent (Sigma-Aldrich)
according to the manufacturer’s protocol. The concentra-
tion of RNA was estimated by measuring the absorbance
at 260 nm (Nano Drop ND-1000 spectrophotometer)
and integrity was verified on a denaturing 1% MOPS-
formaldehyde agarose gel followed by ethidium bromide
staining. For expression profiling, microarray experiments
using whole genome human arrays (4×44K, Agilent) were
used. The microarray hybridizations were performed as
described before [47]. Microarray analysis was performed
by R-Bioconductor (limma package) using subtract method
for background correction [48]. Loess normalization was
applied for dye bias and Quantile normalization was applied
for spatial variation [49]. Linear model and empirical Bayes
methods (limma) was used for assessing differentially
regulated genes [50]. Benjamini Hochberg correction was
applied for P value correction. Hierarchical cluster was
done by Mev4.1 using Euclidean distance metric. The data
was clustered by averaged linkage [51]. Adjusted p value
cut-off was used as 0.05 for differentially regulated genes.
Gene expression data are deposited into GEO (Clone
arrays: GSE40682, Breast cancer tissue arrays: GSE40206).
Real-time qPCR assay
For RT-PCR, cDNA was synthesised from total RNA
using the cDNA Archive kit (Applied Bio systems, USA).
cDNA equivalent to 10 ng of total RNA was used for all
the PCR reactions using Dynamo SYBR green mix
(Finnzymes, Finland) in ABI Prism 7900HT sequence
detection system (Applied Bio systems, USA). The
sequences of the primers are shown in Additional file 9:
Table S5. The analysis has been done using SDS 2.1
software (Applied Bio systems, USA). For normalization
of RT-PCR data, ribosomal protein L35a (RPL 35a) and
TATA Binding Protein (TBP) were used for cells and
tissues, respectively.
Immunoflourescence
Cells were grown on sterile cover-slips till they were about
50% confluent. The growth medium was discarded; cells
were washed twice with chilled DPBS and were fixed in
ice cold methanol for 10 minutes at −20°C. The fixed cells
were then washed with DPBS thrice. For blocking non-
specific binding of the antibodies, the cells were incubated
with 1% BSA in PBS for 60 min followed by overnight
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1:50; IGFBP2, 1:25) in a humidified chamber at 4°C. After
the overnight incubation, the cells were washed thrice
with PBS and incubated with the secondary antibody,
1:1500 dilution of alexa flur 488 (anti-rabbit, for β-catenin)
and alexa flur 633 (anti-goat for IGFBP2) (Molecular
probes, Invitrogen, USA) in PBS for 1 hour in dark. All
steps thereafter were performed in the dark. After 1 h,
the cells were again washed thrice with PBS and
counterstained with 33 μg/ml Propidium Iodide for
5 minutes and mounted in anti‐fade solution on clean
slides. The stained cells were visualized using a confocal
microscope (LSM 510 Meta, Carl-Zeiss) and were
photographed.
Tissue samples and immunohistochemistry
For histology, sections of breast tumor tissues were
obtained from blocks archived in the Department of
Pathology at the Kidwai Memorial Institute of Oncology
(KMIO). The status of estrogen receptor (ER), progester-
one receptor (PR), Her2/neu, and pathological data like
tumor grade, size and lymph node status were obtained
from the pathology records of the respective patients.
Tissue sections (5 μm) from the paraffin embedded
tumor specimens were collected on silane-coated slides
and immunohistochemistry for IGFBP2 and β-catenin
was performed on 38 samples. Antigen retrieval was
done by heat treatment of the deparaffinised sections in
Citrate buffer (10 mM; pH 6.0). After the initial processing
steps, sections were incubated overnight with respective
primary antibodies - IGFBP2 (C-18: sc-6001, Santa Cruz
Biotechnology, Inc, CA) and β-catenin (C 2206, Sigma-
Aldrich), at 4°C. This was followed by incubation with
the linked streptavidin- biotinylated secondary antibody
(Universal LSAB, DAKO, Denmark) for IGFBP2 and
with supersensitive non-biotin horseradish peroxidase
detection system (QD440-XAK, Biogenex) for β-catenin
antibodies. 3, 3’-Diaminobenzidine (Sigma-Aldrich) was
used as the chromogenic substrate.
Evaluation of immunohistochemistry
The scoring method used for IGFBP2 and β-catenin
expression was based on semi quantitative scoring
method as described before [52] where both intensity
and percentage of cells with positive staining were
counted and a combined score was given. The combined
score was arrived by the multiplication product of both
the scores. The scores are, (1) percentage of cells: no
staining = 0; 10% or less of cells stained = 1; 11–50% of
cells stained = 2; and 50% or more of cells stained =3; (2)
intensity: no staining = 0, weak staining = 1, moderate
staining = 2, and strong staining = 3. Thus, the combined
scores ranged from 0–9. Only scores from 4–9 were
considered positive for staining.Statistical analysis
Statistical significance for all experimental analyses
(except microarray) was determined by Student’s t-test
or one-way analysis of variance GraphPad Prism 5.0
software (GraphPad Software, Inc., La Jolla, CA, USA).
For correlation analysis Fisher’s exact test was utilized.Additional files
Additional file 1: List of common probe between IGFBP2
Knockdown clones C5 and C12.
Additional file 2: Figure S1. Gene expression changes in IGFBP2
knockdown cells upon IGFBP2 over expression. Cells were plated and
24 h later transfected with pcDNA3.1-IGFBP2 and /or pcDNA3.1 vector.
48 h post transfection, RNA was extracted and gene expression was
analyzed by Semi quantitative RT-PCR analysis. Representative ethidium
bromide gel shows the expression of genes regulated upon forced
expression of IGFBP2 in a) clone C12 and b) clone C5. Expression values
were quantitated and the graph (right) represents fold change over
control after normalization with the expression of RPL35A.
Additional file 3: List of Differentially expressed probes between
IGFBP2 positive and negative breast tumors.
Additional file 4: Figure S2. Validation of Wnt target genes in IGFBP2
positive and IGFBP2 negative tumors. Scatter plots of differentially
regulated genes in tumor tissues compared to the expression in normal
tissues. Log 2-transformed gene expression ratios obtained from real-time
quantitative PCR analysis normalized to TBP expression are plotted. Each
dot represents data derived from one sample.
Additional file 5: List of differentially regulated probes common
between IGFBP2 knockdown clones and IGFBP2 positive/negative
tumors.
Additional file 6: List of pathways associated with differentially
regulated genes common between IGFBP2 knockdown clones and
IGFBP2 positive/negative tumors.
Additional file 7: Figure S3. Regulation of β-catenin by IGFBP2 is
IGF1R and FAK dependent. MDA-MB-231 cells were transfected with
IGFBP2 and 36 h. after transfection cells were fixed and analyzed for β-
catenin and IGFBP2 protein. For inhibitor treatements, 24 h. after
transfection cells were treated with IGF1R or FAK inhibitor for 12 h. Cells
were fixed and analyzed for β-catenin and IGFBP2 expression. Expression
of β-catenin and IGFBP2 is shown in green and blue, respectively.
Nucleus was stained using propidium iodide (PI) as shown in red Original
magnification was 63×. V, Vector control; OE, Over expression; Inh,
inhibitor.
Additional file 8: Figure S4. Comparison of IGFBP2 regulated genes in
knock down cells with other available data sets. a) Venn diagram
showing genes common between IGFBP2 over expressing glioma cells
(GEO accession no. GSE35467) and IGFBP2 knock down breast cancer
cells (Additional file 1: Table S1). b) Venn diagram showing genes
common between RGE mutant IGFBP2 over expressing glioma cells (GEO
accession no. GSE35467) and IGFBP2 knock down breast cancer cells
(Table S1). OV, over expression; KD, knockdown; RGE, RGE mutant IGFBP2.
Additional file 9: List of primer sequences used for qPCR.Competing interests
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